Virogenbio is a global biotechnology company focused on the development of innovative medicines for immunotherapies for unmet needs in a range of therapeutic areas.

Offices in Singapore (holding company), China (R&D and manufacturing) and the United States (clinical development and alliance management) will be expanded to include presence in the EU.